Table 2 Survival assessed by Kaplan–Meier survival analysis using log-rank test for each variable.
Variables | Data | RFS (log-rank test p-value) | BCSS (log-rank test p-value) |
|---|---|---|---|
Age in years | 0.104 | 0.048a | |
Above median age of 66 years | 35 (50%) | ||
Below median age of 66 years | 35 (50%) | ||
Range | 36–98 years | ||
Procedure | 0.013a | 0.024a | |
Segmental | 42 (60%) | ||
Total mastectomy | 23 (33%) | ||
Modified radical mastectomy | 5 (7%) | ||
Tumor grade | 0.521 | 0.133 | |
I | 10 (14%) | ||
II | 53 (76%) | ||
III | 7 (10%) | ||
Nottingham score | 0.727 | 0.591 | |
4–6 | 37 (53%) | ||
7–9 | 33 (47%) | ||
LN status | 0.028a | 0.036a | |
Negative | 51 (73%) | ||
Positive | 17 (24%) | ||
Not available | 2 (3%) | ||
pT stage | 0.081 | 0.061 | |
1 | 44 (63%) | ||
2 | 18 (26%) | ||
3 | 8 (11%) | ||
pN stage | 0.001a | 0.005a | |
0 | 51 (73%) | ||
1 | 11 (16%) | ||
2 | 4 (6%) | ||
3 | 2 (2.5%) | ||
Unknown | 2 (2.5%) | ||
AJCC Stage | 0.000a | 0.000a | |
I | 39 (56%) | ||
II | 23 (33%) | ||
III | 7 (10%) | ||
IV | 1 (1%) | ||
HER2 immunohistochemistry | 0.651 | 0.860 | |
Score 0 | 13 (19%) | ||
Score 1+ | 20 (28%) | ||
Score 2+/FISH-negative | 37 (53%) | ||
Ki-67 index | 0.942 | 0.508 | |
1–10% | 33 (47%) | ||
11–20% | 21 (30%) | ||
21–30% | 16 (23%) | ||
Stromal TILs | 0.449 | 0.492 | |
1–10% | 49 (70%) | ||
11–30% | 14 (20%) | ||
31% or more | 7 (10%) | ||
Tumor type | 0.977 | 0.576 | |
Apocrine | 49 (70%) | ||
Histiocytoid | 5 (7%) | ||
No special type | 7 (10%) | ||
Other | 9 (13%) | ||
Neoadjuvant chemotherapy | 0.265 | 0.256 | |
No | 52 (74%) | ||
Yes | 18 (26%) | ||
Response to neoadjuvant chemotherapy (n = 18) | 0.199 | 0.60 | |
Residual Cancer Burden 0 | 2 (11%) | ||
Residual Cancer Burden 1 | 0 (0%) | ||
Residual Cancer Burden 2 | 10 (56%) | ||
Residual Cancer Burden 3 | 6 (33%) | ||
Radiation | 0.534 | 0.869 | |
No | 20 (29%) | ||
Yes | 47 (67%) | ||
Unknown | 3 (4%) | ||
Systemic chemotherapy | 0.920 | 0.940 | |
No | 28 (40%) | ||
Yes | 42 (60%) |
